Form 4: Bicycle Therapeutics CEO Sells Shares
Statement of Changes in Beneficial Ownership
Bicycle Therapeutics CEO Kevin Lee reported the sale of 7,642 ordinary shares, a transaction related to tax withholding obligations upon RSU vesting.
Summary
- Kevin Lee, Chief Executive Officer and Director of Bicycle Therapeutics PLC, reported a disposition of 7,642 ordinary shares.
- The transactions occurred on July 2, 2026, and July 6, 2026.
- The sales were conducted to cover statutory tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).
- This type of sale is mandated by the award agreement and is not considered a discretionary sale by the reporting person.
- Following these transactions, Kevin Lee beneficially owns 603,671 ordinary shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the share sales are mandated for tax purposes and do not reflect a lack of confidence by the CEO.
Positives
- The sales were not discretionary but were mandated to cover tax obligations, indicating no change in the CEO's confidence in the company.
- The CEO retains a significant beneficial ownership of 603,671 ordinary shares, demonstrating continued commitment.
Negatives
- A total of 7,642 shares were sold, reducing the CEO's direct holdings.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on past transactions.
Management Comments
- The sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary sale by the Reporting Person.
Industry Context
StockSavvy.ai notes that insider sales for tax withholding purposes are common events, particularly following RSU vesting, and are generally not interpreted as a negative signal about the company's prospects.
Stakeholder Impact
- Shareholders: The sale is a routine event for tax withholding and is not expected to significantly impact the share price or reflect negatively on the company's performance.
Key Dates
| Date | Description |
|---|---|
| 07/02/2026 | Earliest transaction date reported. |
| 07/02/2026 | Transaction date for the sale of 5,905 ordinary shares. |
| 07/06/2026 | Transaction date for the sale of 1,737 ordinary shares. |
| 07/07/2026 | Date of signature for the filing. |
Keywords
Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.